Biweekly Docetaxel and S-1 Combination Chemotherapy as First-line Treatment for Elderly Patients with Advanced Gastric Cancer

被引：1

作者：

Kunisaki, Chikara ^{[1
]}

Takahashi, Masazumi ^{[2
]}

Ono, Hidetaka A. ^{[1
]}

Hasegawa, Shinichi ^{[1
]}

Tsuchida, Kazuhito ^{[1
]}

Oshima, Takashi ^{[1
]}

Ota, Mitsuyoshi ^{[1
]}

Fukushima, Tadao ^{[1
]}

Tokuhisa, Motohiko ^{[3
]}

Izumisawa, Yusuice ^{[3
]}

Takagawa, Ryo ^{[3
]}

Kimura, Jun ^{[3
]}

Kosaka, Takashi ^{[3
]}

Makino, Hirochika ^{[3
]}

Akiyama, Hirotoshi ^{[3
]}

Endo, Itaru ^{[3
]}

机构：

[1] Yokohama City Univ, Dept Surg, Gastroenterol Ctr, Minami Ku, Yokohama, Kanagawa 2320024, Japan

[2] Yokohama Municipal Hosp, Dept Surg, Hodogaya Ku, Yokohama, Kanagawa, Japan

[3] Yokohama City Univ, Dept Surg Gastroenterol, Kanazawa Ku, Yokohama, Kanagawa 2320024, Japan

来源：

ANTICANCER RESEARCH | 2013年 / 33卷 / 02期

关键词：

Advanced gastric cancer; chemotherapy; docetaxel; elderly; S-1; ADVANCED ESOPHAGOGASTRIC CANCER; PHASE-III TRIAL; PLUS CISPLATIN; LEUCOVORIN; FLUOROURACIL; THERAPY; ADENOCARCINOMA; OXALIPLATIN; MULTICENTER; I/II;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: This study assessed the toxicity and activity of biweekly docetaxel and S-1 combination therapy in elderly patients with advanced gastric cancer. Patients and Methods: One-hundred and thirteen patients were enrolled: 35 were 75 years old or more. The objective response rate, toxicity, progression-free survival (PFS), and overall survival (OS) were compared. Results: Dose reduction was significantly frequent in the elderly group (24135 versus 25178, p<0.001). The overall response rate was 54.9%. Out of these, 18 (15.9%) underwent gastrectomy (13 R0 gastrectomy). The median OS was 17.3 months and the median PFS was 8.0 months. Neutropenia was the most frequently observed hematological toxicity at grade 3 and 4 (34.5%), followed by leukopenia (24.8%). Most non-hematological toxicities were of grade 1 or 2. There were no significant differences in overall response rate, median OS, median PFS, or toxicities between the two groups. Conclusion: This combination offers favourable survival benefits with controllable tolerance for therapy of AGC in the elderly.

引用

页码：697 / 704

页数：8

共 50 条

[1] Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer
Chikara Kunisaki
Masazumi Takahashi
Hirochika Makino
Takashi Oshima
Shoichi Fujii
Ryo Takagawa
Jun Kimura
Takashi Kosaka
Hidetaka A. Ono
Hirotoshi Akiyama
Kunio Kameda
Fumihiko Kito
Satoshi Morita
Itaru Endo
[J]. Cancer Chemotherapy and Pharmacology, 2011, 67 : 1363 - 1368
[2] Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer
Kunisaki, Chikara
Takahashi, Masazumi
Makino, Hirochika
Oshima, Takashi
Fujii, Shoichi
Takagawa, Ryo
Kimura, Jun
Kosaka, Takashi
Ono, Hidetaka A.
Akiyama, Hirotoshi
Kameda, Kunio
Kito, Fumihiko
Morita, Satoshi
Endo, Itaru
[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (06) : 1363 - 1368
[3] Combination Chemotherapy with S-1 and Oxaliplatin (SOX) as First-Line Treatment in Elderly Patients with Advanced Gastric Cancer
Zhong, Dong-ta
Wu, Ri-ping
Wang, Xin-li
Huang, Xiao-bing
Lin, Meng-xin
Lan, Yan-qin
Chen, Qiang
[J]. PATHOLOGY & ONCOLOGY RESEARCH, 2015, 21 (04) : 867 - 873
[4] Docetaxel and S-1 as a First-line Treatment in Patients with Advanced or Recurrent Gastric Cancer
Tsutani, Yasuhiro
Ohara, Masahiro
Suzuki, Takahisa
Minami, Kazuhito
Miyahara, Eiji
Kameda, Akira
Noso, Yoshihiro
[J]. ANTICANCER RESEARCH, 2009, 29 (07) : 2775 - 2779
[5] Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis
Kazuaki Tanabe
Takahisa Suzuki
Noriaki Tokumoto
Hideki Yamamoto
Kazuhiro Yoshida
Hideki Ohdan
[J]. World Journal of Surgical Oncology, 8
[6] Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis
Tanabe, Kazuaki
Suzuki, Takahisa
Tokumoto, Noriaki
Yamamoto, Hideki
Yoshida, Kazuhiro
Ohdan, Hideki
[J]. WORLD JOURNAL OF SURGICAL ONCOLOGY, 2010, 8
[7] A phase II study of biweekly oxaliplatin plus S-1 combination chemotherapy as a first-line treatment for patients with metastatic or advanced gastric cancer in China
Xiao, Cheng
Qian, Jiong
Zheng, Yulong
Song, Fang
Wang, Qiangfeng
Jiang, Haiping
Mao, Chenyu
Xu, Nong
[J]. MEDICINE, 2019, 98 (20)
[8] Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer
Quintero-Aldana, G.
Jorge, M.
Grande, C.
Salgado, M.
Gallardo, E.
Varela, S.
Lopez, C.
Villanueva, M. J.
Fernandez, A.
Alvarez, E.
Gonzalez, P.
Castellanos, J.
Casal, J.
Lopez, R.
Campos Balea, B.
[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 731 - 737
[9] Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer
G. Quintero-Aldana
M. Jorge
C. Grande
M. Salgado
E. Gallardo
S. Varela
C. López
M. J. Villanueva
A. Fernández
E. Alvarez
P. González
J. Castellanos
J. Casal
R. López
B. Campos Balea
[J]. Cancer Chemotherapy and Pharmacology, 2015, 76 : 731 - 737
[10] Phase II study of biweekly docetaxel and cisplatin combination chemotherapy in first-line advanced gastric cancer
Quintero, G., Sr.
Jorge, M.
Casal, J.
Salgado, M.
Candamio, S.
Lopez, R.
Mel, J. R.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

← 1 2 3 4 5 →